✨ Free AI Report
Matinas BioPharma Holdings, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Matinas BioPharma Holdings, Inc.
Company Research

Matinas BioPharma Holdings, Inc.: Business Overview, Financials & Competitive Analysis

Matinas BioPharma is a clinical-stage biopharmaceutical company that identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's lead candidate MAT2203 is an or...

Analyst-debate audio for Matinas BioPharma Holdings, Inc.

AskCyborg analysts argue the bull and bear cases for Matinas BioPharma Holdings, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
5/ 10Mixed

Cyborg Score thesis

Platform technology with differentiated delivery mechanism addresses high-unmet-need infections, but success depends on Phase III...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Clinical Stage / Drug Delivery
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Matinas BioPharma Holdings, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Matinas BioPharma Holdings, Inc. Overview

Pro stress-test →

Matinas BioPharma is a clinical-stage biopharmaceutical company that identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's lead candidate MAT2203 is an orally administered formulation of amphotericin B, a broad spectrum fungicidal agent, positioned to potentially replace more invasive administration methods.

Strategic Profile

Pro stress-test →

Matinas is focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology. The company's focus on anti-infectives underscores its commitment to addressing areas of high unmet medical need and harnessing its expertise in reformulating established therapeutic agents for enhanced patient outcomes.

Competitive Landscape

Pro stress-test →

Matinas competes in the clinical-stage anti-infective and drug delivery space against established pharmaceutical companies and other biotech firms developing novel infectious disease treatments. The company's differentiated LNC platform for oral delivery of traditional IV-only drugs provides a competitive edge in unmet needs for invasive fungal infections and multidrug-resistant bacteria.

Industry Context

Matinas BioPharma Holdings, Inc. operates in Biopharmaceutical - Clinical Stage / Drug Delivery.

Key facts

Founded: 2013 · Headquarters: Bedminster, New Jersey, US

What the analysts stress-tested

The top findings that survived the multi-agent debate for Matinas BioPharma Holdings, Inc..

  • LNC platform enables oral delivery of previously IV-only medicines, reducing treatment burden and adverse events
  • MAT2203 (oral amphotericin B) in Phase III ORALTO trial for invasive fungal infections with compassionate use showing clinical responses
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Mar 2024Matinas reports completion of clinical response in three patients with invasive fusarium infection treated with MAT2203 under Compassionate Use Program
  • Feb 2025Appointment of Evelyn D'An to Board of Directors as independent director
  • +1 moreTrack every material event for Matinas BioPharma Holdings, Inc. as it happens. Explore monitoring →
Get alerted when Matinas BioPharma Holdings, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Conventional amphotericin B formulationsEstablished IV-based antifungal products→Other oral antifungal candidatesEarly-stage oral antifungal development programs→Antibiotic therapiesConventional treatment options for bacterial infections→

Compare Matinas BioPharma Holdings, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Matinas BioPharma Holdings, Inc. operates in Biopharmaceutical - Clinical Stage / Drug Delivery. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Clinical Stage / Drug Delivery research →
NEW · MCP server

Ask your AI assistant about Matinas BioPharma Holdings, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Matinas BioPharma Holdings, Inc. and its top competitor on Cyborg Score”
“What did Matinas BioPharma Holdings, Inc. do this quarter?”
“Is Matinas BioPharma Holdings, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Matinas BioPharma Holdings, Inc. do?+
Matinas BioPharma is a clinical-stage biopharmaceutical company that identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's lead candidate MAT2203 is an or...
What is Matinas BioPharma Holdings, Inc.'s Cyborg Score?+
Matinas BioPharma Holdings, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Matinas BioPharma Holdings, Inc.'s main competitors?+
Named competitors include Conventional amphotericin B formulations, Other oral antifungal candidates, Antibiotic therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Matinas BioPharma Holdings, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Matinas BioPharma Holdings, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Matinas BioPharma Holdings, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical - Clinical Stage research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6Scholar Rock Holding Corporation5Corbus Pharmaceuticals Holdings, Inc.5Jasper Therapeutics, Inc.3Aardvark Therapeutics, Inc.3Mereo BioPharma Group plc